berberine sulfate

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

aphthous ulcer (canker sores)

[Possibly Effective]

Dose: apply 0.5% gel topically qid

atrial fibrillation

[Insufficient Evidence]

Dose: 400 mg PO tid

biliary disorder

[Insufficient Evidence]

Dose: 500-1000 mg PO bid

burns

[Insufficient Evidence]

Dose: apply ointment topically q4h

CHF

[Insufficient Evidence]

Dose: 1.2-2 g PO qd; Info: used with conventional tx

cholera

[Insufficient Evidence]

Dose: 400 mg PO x1

colorectal adenoma

[Insufficient Evidence]

Dose: 300 mg PO bid; Alt: 100 mg PO tid

coronary heart disease

[Insufficient Evidence]

Dose: 500 mg PO qd

diabetes mellitus, type 2

[Possibly Effective]

Dose: 500 mg PO bid-tid; Alt: 0.9-3 g/day PO divided bid-tid; 600 mg PO bid; Info: used with or without conventional tx

diarrhea

[Insufficient Evidence]

Dose: 400 mg PO x1

diarrhea, radiation-related

[Insufficient Evidence]

Dose: 300 mg PO tid

hepatitis B

[Insufficient Evidence]

Dose: 1 g PO qd

hepatitis C

[Insufficient Evidence]

Dose: 1 g PO qd

H. pylori infection

[Possibly Effective]

Dose: 300-500 mg PO bid-tid; Info: used with standard tx

HTN

[Possibly Effective]

Dose: 900 mg PO qd; Info: used with amlodipine

hyperlipidemia

[Possibly Effective]

Dose: 500-1000 mg PO qd-bid; Alt: 200-500 mg PO tid

IBS

[Insufficient Evidence]

Dose: 200-400 mg PO bid

impaired glucose tolerance

[Insufficient Evidence]

Dose: 500 mg extract PO tid; Alt: 550 mg PO bid

metabolic dysfunction-associated steatotic liver disease

[Insufficient Evidence]

Dose: 500-1000 mg PO bid; Alt: 200-500 mg PO tid; Info: used with or without metformin

metabolic effects, antipsychotic-induced

[Insufficient Evidence]

Dose: 300 mg PO bid

metabolic syndrome

[Insufficient Evidence]

Dose: 500 mg PO tid; Alt: 500 mg PO qd

obesity

[Insufficient Evidence]

Dose: 300-1500 mg PO qd

polycystic ovary syndrome

[Possibly Effective]

Dose: 500-550 mg PO bid-tid; Alt: 900 mg PO qd

radiation fibrosis

[Insufficient Evidence]

Dose: 20 mg/kg/dose PO qd; Start: 1st day of XRT

stroke

[Insufficient Evidence]

Dose: 300-1000 mg PO qd; Info: used with conventional tx

thrombocytopenia

[Insufficient Evidence]

Dose: 5 mg PO tid

trachoma, adult patients

[Insufficient Evidence]

Dose: 1 drop in eye(s) tid; Info: 0.2% or 0.5% solution

trachoma, peds patients

[Insufficient Evidence]

Dose: 1 drop 0.2% in eye(s) tid

ulcerative colitis

[Insufficient Evidence]

Dose: 0.6-0.9 g PO qd; Alt: 4-6 g PR qd; Info: used with mesalamine

ventricular arrhythmias

[Insufficient Evidence]

Dose: 300-600 mg PO tid-qid; Info: used with or without antiarrhythmic tx